Enhancing photodynamic therapy of refractory solid cancers: Combining second-generation photosensitizers with multi-targeted liposomal delivery

Ruud Weijer, Mans Broekgaarden, Milan Kos, Remko van Vught, Erik A.J. Rauws, Eefjan Breukink, Thomas M. van Gulik, Gert Storm, Michal Heger

Research output: Contribution to journalReview articleAcademicpeer-review

54 Citations (Scopus)

Abstract

Contemporary photodynamic therapy (PDT) for the last-line treatment of refractory cancers such as nasopharyngeal carcinomas, superficial recurrent urothelial carcinomas, and non-resectable extrahepatic cholangiocarcinomas yields poor clinical outcomes and may be associated with adverse events. This is mainly attributable to three factors: (1) the currently employed photosensitizers exhibit suboptimal spectral properties, (2) the route of administration is associated with unfavorable photosensitizer pharmacokinetics, and (3) the upregulation of survival pathways in tumor cells may impede cell death after PDT. Consequently, there is a strong medical need to improve PDT of these recalcitrant cancers. An increase in PDT efficacy and reduction in clinical side-effects may be achieved by encapsulating second-generation photosensitizers into liposomes that selectively target to pharmacologically important tumor locations, namely tumor cells, tumor endothelium, and tumor interstitial spaces. In addition to addressing the drawbacks of clinically approved photosensitizers, this review addresses the most relevant pharmacological aspects that dictate clinical outcome, including photosensitizer biodistribution and intracellular localization in relation to PDT efficacy, the mechanisms of PDT-induced cell death, and PDT-induced antitumor immune responses. Also, a rationale is provided for the use of second-generation photosensitizers such as diamagnetic phthalocyanines (e.g., zinc or aluminum phthalocyanine), which exhibit superior photophysical and photochemical properties, in combination with a multi-targeted liposomal photosensitizer delivery system. The rationale for this PDT platform is corroborated by preliminary experimental data and proof-of-concept studies. Finally, a summary of the different nanoparticulate photosensitizer delivery systems is provided followed by a section on phototriggered release mechanisms in the context of liposomal photosensitizer delivery systems.

Original languageEnglish
Pages (from-to)103-131
Number of pages29
JournalJournal of Photochemistry and Photobiology C: Photochemistry Reviews
Volume23
DOIs
Publication statusPublished - 1 Jun 2015

Fingerprint

Photodynamic therapy
Photosensitizing Agents
Photosensitizers
refractories
Refractory materials
therapy
delivery
cancer
tumors
Tumors
death
Cell death
endothelium
Cells
encapsulating
Pharmacokinetics
Liposomes
interstitials
platforms
zinc

Keywords

  • Cancer
  • Drug delivery
  • Metallated phthalocyanines
  • Photodynamic therapy
  • Photosensitizers
  • Reactive oxygen species
  • Singlet oxygen
  • Tumor targeting

Cite this

Weijer, Ruud ; Broekgaarden, Mans ; Kos, Milan ; van Vught, Remko ; Rauws, Erik A.J. ; Breukink, Eefjan ; van Gulik, Thomas M. ; Storm, Gert ; Heger, Michal. / Enhancing photodynamic therapy of refractory solid cancers : Combining second-generation photosensitizers with multi-targeted liposomal delivery. In: Journal of Photochemistry and Photobiology C: Photochemistry Reviews. 2015 ; Vol. 23. pp. 103-131.
@article{c8e5e7f531614f719d6ce056b61a93be,
title = "Enhancing photodynamic therapy of refractory solid cancers: Combining second-generation photosensitizers with multi-targeted liposomal delivery",
abstract = "Contemporary photodynamic therapy (PDT) for the last-line treatment of refractory cancers such as nasopharyngeal carcinomas, superficial recurrent urothelial carcinomas, and non-resectable extrahepatic cholangiocarcinomas yields poor clinical outcomes and may be associated with adverse events. This is mainly attributable to three factors: (1) the currently employed photosensitizers exhibit suboptimal spectral properties, (2) the route of administration is associated with unfavorable photosensitizer pharmacokinetics, and (3) the upregulation of survival pathways in tumor cells may impede cell death after PDT. Consequently, there is a strong medical need to improve PDT of these recalcitrant cancers. An increase in PDT efficacy and reduction in clinical side-effects may be achieved by encapsulating second-generation photosensitizers into liposomes that selectively target to pharmacologically important tumor locations, namely tumor cells, tumor endothelium, and tumor interstitial spaces. In addition to addressing the drawbacks of clinically approved photosensitizers, this review addresses the most relevant pharmacological aspects that dictate clinical outcome, including photosensitizer biodistribution and intracellular localization in relation to PDT efficacy, the mechanisms of PDT-induced cell death, and PDT-induced antitumor immune responses. Also, a rationale is provided for the use of second-generation photosensitizers such as diamagnetic phthalocyanines (e.g., zinc or aluminum phthalocyanine), which exhibit superior photophysical and photochemical properties, in combination with a multi-targeted liposomal photosensitizer delivery system. The rationale for this PDT platform is corroborated by preliminary experimental data and proof-of-concept studies. Finally, a summary of the different nanoparticulate photosensitizer delivery systems is provided followed by a section on phototriggered release mechanisms in the context of liposomal photosensitizer delivery systems.",
keywords = "Cancer, Drug delivery, Metallated phthalocyanines, Photodynamic therapy, Photosensitizers, Reactive oxygen species, Singlet oxygen, Tumor targeting",
author = "Ruud Weijer and Mans Broekgaarden and Milan Kos and {van Vught}, Remko and Rauws, {Erik A.J.} and Eefjan Breukink and {van Gulik}, {Thomas M.} and Gert Storm and Michal Heger",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.jphotochemrev.2015.05.002",
language = "English",
volume = "23",
pages = "103--131",
journal = "Journal of Photochemistry and Photobiology C: Photochemistry Reviews",
issn = "1389-5567",
publisher = "Elsevier",

}

Enhancing photodynamic therapy of refractory solid cancers : Combining second-generation photosensitizers with multi-targeted liposomal delivery. / Weijer, Ruud; Broekgaarden, Mans; Kos, Milan; van Vught, Remko; Rauws, Erik A.J.; Breukink, Eefjan; van Gulik, Thomas M.; Storm, Gert; Heger, Michal.

In: Journal of Photochemistry and Photobiology C: Photochemistry Reviews, Vol. 23, 01.06.2015, p. 103-131.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Enhancing photodynamic therapy of refractory solid cancers

T2 - Combining second-generation photosensitizers with multi-targeted liposomal delivery

AU - Weijer, Ruud

AU - Broekgaarden, Mans

AU - Kos, Milan

AU - van Vught, Remko

AU - Rauws, Erik A.J.

AU - Breukink, Eefjan

AU - van Gulik, Thomas M.

AU - Storm, Gert

AU - Heger, Michal

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Contemporary photodynamic therapy (PDT) for the last-line treatment of refractory cancers such as nasopharyngeal carcinomas, superficial recurrent urothelial carcinomas, and non-resectable extrahepatic cholangiocarcinomas yields poor clinical outcomes and may be associated with adverse events. This is mainly attributable to three factors: (1) the currently employed photosensitizers exhibit suboptimal spectral properties, (2) the route of administration is associated with unfavorable photosensitizer pharmacokinetics, and (3) the upregulation of survival pathways in tumor cells may impede cell death after PDT. Consequently, there is a strong medical need to improve PDT of these recalcitrant cancers. An increase in PDT efficacy and reduction in clinical side-effects may be achieved by encapsulating second-generation photosensitizers into liposomes that selectively target to pharmacologically important tumor locations, namely tumor cells, tumor endothelium, and tumor interstitial spaces. In addition to addressing the drawbacks of clinically approved photosensitizers, this review addresses the most relevant pharmacological aspects that dictate clinical outcome, including photosensitizer biodistribution and intracellular localization in relation to PDT efficacy, the mechanisms of PDT-induced cell death, and PDT-induced antitumor immune responses. Also, a rationale is provided for the use of second-generation photosensitizers such as diamagnetic phthalocyanines (e.g., zinc or aluminum phthalocyanine), which exhibit superior photophysical and photochemical properties, in combination with a multi-targeted liposomal photosensitizer delivery system. The rationale for this PDT platform is corroborated by preliminary experimental data and proof-of-concept studies. Finally, a summary of the different nanoparticulate photosensitizer delivery systems is provided followed by a section on phototriggered release mechanisms in the context of liposomal photosensitizer delivery systems.

AB - Contemporary photodynamic therapy (PDT) for the last-line treatment of refractory cancers such as nasopharyngeal carcinomas, superficial recurrent urothelial carcinomas, and non-resectable extrahepatic cholangiocarcinomas yields poor clinical outcomes and may be associated with adverse events. This is mainly attributable to three factors: (1) the currently employed photosensitizers exhibit suboptimal spectral properties, (2) the route of administration is associated with unfavorable photosensitizer pharmacokinetics, and (3) the upregulation of survival pathways in tumor cells may impede cell death after PDT. Consequently, there is a strong medical need to improve PDT of these recalcitrant cancers. An increase in PDT efficacy and reduction in clinical side-effects may be achieved by encapsulating second-generation photosensitizers into liposomes that selectively target to pharmacologically important tumor locations, namely tumor cells, tumor endothelium, and tumor interstitial spaces. In addition to addressing the drawbacks of clinically approved photosensitizers, this review addresses the most relevant pharmacological aspects that dictate clinical outcome, including photosensitizer biodistribution and intracellular localization in relation to PDT efficacy, the mechanisms of PDT-induced cell death, and PDT-induced antitumor immune responses. Also, a rationale is provided for the use of second-generation photosensitizers such as diamagnetic phthalocyanines (e.g., zinc or aluminum phthalocyanine), which exhibit superior photophysical and photochemical properties, in combination with a multi-targeted liposomal photosensitizer delivery system. The rationale for this PDT platform is corroborated by preliminary experimental data and proof-of-concept studies. Finally, a summary of the different nanoparticulate photosensitizer delivery systems is provided followed by a section on phototriggered release mechanisms in the context of liposomal photosensitizer delivery systems.

KW - Cancer

KW - Drug delivery

KW - Metallated phthalocyanines

KW - Photodynamic therapy

KW - Photosensitizers

KW - Reactive oxygen species

KW - Singlet oxygen

KW - Tumor targeting

UR - http://www.scopus.com/inward/record.url?scp=84938826215&partnerID=8YFLogxK

U2 - 10.1016/j.jphotochemrev.2015.05.002

DO - 10.1016/j.jphotochemrev.2015.05.002

M3 - Review article

VL - 23

SP - 103

EP - 131

JO - Journal of Photochemistry and Photobiology C: Photochemistry Reviews

JF - Journal of Photochemistry and Photobiology C: Photochemistry Reviews

SN - 1389-5567

ER -